OTCMKTS:ANTH - Anthera Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.07
▼ -0.0015 (-2.10%)
1 month | 3 months | 12 months
Get New Anthera Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANTH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANTH

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Anthera Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.07.
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in Anthera Pharmaceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
3/15/2018Jefferies Financial GroupReiterated RatingHold$0.50
i
3/12/2018Piper Jaffray CompaniesDowngradeOverweight ➝ Underweight
i
3/6/2018HC WainwrightReiterated RatingBuy
i
Rating by A. Fein at HC Wainwright
2/21/2018Roth CapitalInitiated CoverageBuy ➝ Buy$10.00 ➝ $10.00
i
Rating by J. Marango at Roth Capital
9/19/2017HC WainwrightReiterated RatingBuy$3.00
i
8/11/2017Jefferies Financial GroupReiterated RatingHold$2.25 ➝ $1.75
i
Rating by Matthew Andrews at Jefferies Financial Group Inc.
5/15/2017Jefferies Financial GroupReiterated RatingHold$2.25
i
Rating by Matthew Andrews at Jefferies Financial Group Inc.
3/6/2017Jefferies Financial GroupLower Price TargetHold$8.00 ➝ $6.40
i
12/29/2016Piper Jaffray CompaniesLower Price TargetOverweight$56.00 ➝ $10.80
i
12/29/2016Jefferies Financial GroupDowngradeBuy ➝ Hold$40.00 ➝ $8.00
i
12/29/2016CitigroupDowngradeBuy ➝ Neutral
i
12/29/2016HC WainwrightReiterated RatingBuy$80.00 ➝ $24.00
i
Rating by Andrew Fein at HC Wainwright
12/28/2016SunTrust BanksDowngradeBuy ➝ Hold$48.00 ➝ $8.00
i
8/10/2016Jefferies Financial GroupReiterated RatingBuy
i
Rating by Chris Howerton at Jefferies Financial Group Inc.
7/8/2016HC WainwrightInitiated CoverageBuy$80.00
i
Rating by A. Fein at HC Wainwright
6/30/2016Jefferies Financial GroupReiterated RatingBuy
i
Rating by Chris Howerton at Jefferies Financial Group Inc.
6/20/2016(FBRC)Reiterated RatingHold
i
Rating by Steven Halper at (FBRC)
6/9/2016Jefferies Financial GroupReiterated RatingBuy
i
(Data available from 4/19/2016 forward)
Anthera Pharmaceuticals logo
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
Read More

Today's Range

Now: $0.07
$0.05
$0.07

50 Day Range

MA: $0.09
$0.06
$0.15

52 Week Range

Now: $0.07
$0.01
$0.19

Volume

21,700 shs

Average Volume

197,324 shs

Market Capitalization

$969,500.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.19

Frequently Asked Questions

What sell-side analysts currently cover shares of Anthera Pharmaceuticals?

The following sell-side analysts have issued reports on Anthera Pharmaceuticals in the last year:
View the latest analyst ratings for ANTH.

What is the current price target for Anthera Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Anthera Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Anthera Pharmaceuticals in the next year.
View the latest price targets for ANTH.

What is the current consensus analyst rating for Anthera Pharmaceuticals?

Anthera Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ANTH.

What other companies compete with Anthera Pharmaceuticals?

How do I contact Anthera Pharmaceuticals' investor relations team?

Anthera Pharmaceuticals' physical mailing address is 25801 INDUSTRIAL BOULEVARD SUITE B, HAYWARD CA, 94545. The biopharmaceutical company's listed phone number is 510-856-5600. The official website for Anthera Pharmaceuticals is www.anthera.com.